



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

21 May 2026
EMADOC-1829012207-51979
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (initial authorisation)

Boey

trenibotulinumtoxinE

On 21 May 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorisation for the medicinal product Boey, intended for the temporary improvement in the appearance of lines between the eyebrows when frowning, when these lines have an important psychological impact in adults.

The applicant for this medicinal product is AbbVie Limited.

Boey will be available as a 1400 units powder for solution for injection. The active substance of Boey, trenibotulinumtoxinE, is a botulinum toxin (ATC code: not yet assigned). It is produced by the bacterium *Clostridium botulinum* and blocks the release of acetylcholine in the neuromuscular synapses, preventing the contraction of muscle cells.

The benefits of Boey are its ability to temporarily reduce the severity of the glabellar lines following local muscular paralysis, with an early onset and short duration of the effect. The most common side effects with Boey include eyelid ptosis, brow ptosis and Mephisto sign (lateral elevation of eyebrow).

The full indication is:

Boey is indicated for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines), when these have an important psychological impact in adult patients (see section 5.1).

Boey should only be administered by physicians with the appropriate qualifications and expertise in the treatment of glabellar lines and the use of required equipment.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

